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Abstract 
Background: Metastatic renal cell carcinoma (RCC) to the liver portrays a poor prognosis 
and liver directed therapy remains controversial. We aimed to determine potential selection 
criteria for patients who might benefit from this strategy.  
Materials and Methods: We evaluated 247 consecutive patients with RCC metastatic to 
the liver from a prospectively maintained database.  
Results: Eighteen patients received liver directed therapy (18/247, 7%). Ten patients un-
derwent liver resection (10/247, 4%) and eight patients underwent radiofrequency ablation 
(RFA, 8/247, 3%). All were rendered free of disease in the liver. Five had synchronous liver 
disease and underwent synchronous resections with their primary. Mortality was 0%. Four-
teen had single (surgery 7, RFA 7) and four (surgery 3, RFA 1) had multiple liver lesions, 
respectively. Median size of lesions was 5cm (0.5 – 10cm) and 2.5cm (1 – 6cm) in the surgery 
and RFA groups, respectively. Median DFI was 10 months, and no difference was observed in 
those with a longer vs. shorter than median DFI (p = 0.95); liver specific progression free 
survival for the surgery and RFA groups were 4 and 6 months, respectively (p= 0.93). 1, 3 and 
5-year actuarial survivals for the whole group were 89%, 40%, 27%. Median survival for the 
surgery group was 24 (3 to 254+) months, and for the RFA group 15.6 (7-56+) months (p = 
0.56). Metachronous liver disease was associated with prolonged survival (p = 0.02).  
Conclusions: Liver directed therapy for RCC is safe. For highly selected patients with 
metachronous liver RCC metastases, liver directed therapy should be considered in a mul-
tidisciplinary manner. 
Key words: liver resection; metastatic renal cell carcinoma; liver metastases; radiofrequency abla-
tion. 
Introduction 
The incidence of renal cell carcinoma (RCC) is 
rising  with  approximately  58,240  new  cases  and 
13,040 deaths estimated for 2010 [1]. 30% of patients 
with RCC will present with metastases and upwards 
of  50%  of  patients  will  develop  metastatic  disease 
with 20 to 40% of patients having disease in the liver 
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[2]. Metastatic RCC portends a poor prognosis and is 
relatively  resistant  to  systemic  therapy.  5-year  sur-
vival rates are poor with only 20% of patients surviv-
ing  with  metastatic  disease  [3].  Median  survival  in 
these patients has been measured to range from 10 to 
20 months. Patients  with  hepatic disease have been 
found  to  live  a  median  of  7.4  months  [4].  As  with 
other solid cancers metastatic to the liver, once RCC 
metastasizes to the liver it is often the rate-limiting 
step for survival.  
Currently, there is a paucity of data to support 
liver directed therapy for metastatic RCC. Although, 
survival could be significantly improved after resec-
tion of lung metastases, treatment of liver metastases 
with either surgery or radiofrequency ablation (RFA) 
remains  uncommon  and  controversial  [3].  To  date, 
there  are  only  20  published  studies  involving  liver 
resection  for  RCC  with  only  7  series  reporting  on 
more  than  ten  patients  (Table  1)  [3].  Therefore,  we 
investigated our experience with liver directed ther-
apy for RCC in order to determine potential selection 
criteria  for  patients  who  might  benefit  from  this 
strategy. 
Materials and Methods 
Patients  
This is a retrospective review of a prospectively 
maintained database of patients with RCC metastatic 
to the liver (n = 247) at the National Cancer Institute, 
NIH  (Bethesda,  USA)  from  1980  to  2010.  Eighteen 
patients  underwent  liver  directed  therapy  (18/247). 
Ten (10/247) patients underwent liver resection and 
eight  (8/247)  patients  underwent  RFA.  All  patients 
signed  institutional review board approved consent 
for participation in clinical studies. Resectable extra-
hepatic metastases were not considered a contraindi-
cation.  
 
 
Table 1.  Literature review of liver resection for metastatic renal cell carcinoma. 
Author  Year  Patients  Survival 
Foster  1978  5  Died at 2, 6, 7, 33, 144 months 
Morrow et al.  1982  1  Alive at 5 years 
Thompson et al.  1983  1  No survival data 
Iwatsuki  1988  3  No survival data 
Pontes et al.  1989  2  No survival data 
Tongaonkar et al.  1992  1  Died at 10 months 
Antoniewicz et al.  1994  2  Died at 8, 24 months 
Bennett et al. 
 
1995 
 
4 
 
Two died at 13, 14 months 
Two Alive at 21 and 32 months 
Harrison et al.  1997  5  Three alive at 5 years 
Stief et al.  1997  13  Mean survival 16 months 
Fujisaki et al. 
 
1997 
 
3 
 
Two died at 10, 18 months 
One alive at 12 months 
Kawata et al.  2000  4  Two alive at 24 months 
Karavias et al.  2002  6  One died at 12 months, 5 alive at 5 years 
Alves et al.  2003  14  Median survival 26 months 
Weitz et al.  2005  11  Two alive at 24 months 
Aloia et al.  2005  19  Median survival 36 months 
Thelen et al.  2007  31  1 yr, 3yr, 5yr survival: 82%, 54%, 39% 
Yezhelyev et al.  2009  6  No survival data 
Staehler et al.  2010  68  Median survival 142 months 
5 yr survival: 62% 
Ruys et al.  2011  33  1 yr, 3yr, 5yr survival: 79%, 47%, 43% 
Langan et al.  2011  18  Median survival: (surgery 24 mn, RFA 15.6 mn) 
1 yr, 3yr, 5yr survival: 89%, 40%, 27% 
Total  ‘78 – ‘11  250   
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Statistical Analysis 
Overall survival (OS) was calculated from date 
of liver directed therapy to last encounter, or death. 
For patients resected to no evidence of disease (NED), 
disease-free  survival  (DFS)  was  calculated  from  he-
patic resection to first recurrence, or to last follow-up 
without  recurrence.  Liver  recurrence-free  survival 
(RFS)  was  calculated  from  date  of  liver  directed 
therapy until death, last follow-up or date of first liver 
progression. For patients with residual disease after 
liver directed therapy, progression-free survival (PFS) 
was calculated from date of liver directed therapy to 
progression at any site or last follow-up without pro-
gression.  The  disease  free  interval  (DFI)  was  calcu-
lated  from  time  of  initial  surgery  when  resected  to 
NED until first recurrence at any site. The probabili-
ties  of  survival,  liver  RFS,  DFS,  PFS  and  DFI  were 
calculated by the Kaplan-Meier method; the statistical 
significance  of  differences  between  pairs  of 
Kaplan-Meier curves was determined by the log-rank 
test for cases in which the distinguishing characteris-
tics of the curve were known at the date of resection. 
Clinicopathologic  features  were  evaluated  for  their 
association with outcome by univariate methods de-
scribed  above.  All  p-values  are  two  tailed  and  are 
presented without adjustment for multiple compari-
sons.  
Results 
Patient Characteristics 
Inclusion criteria included patients who under-
went  liver  resection  or  RFA  for  pathologically  con-
firmed RCC metastatic to the liver. Patients were ex-
cluded if liver therapy was not delivered at the NCI, 
final pathology was benign, liver resection occurred 
for extension of the primary into the liver, and pa-
tients  who  received  systemic  therapy  only.  Median 
age of patients who underwent liver resection was 47 
(range 32 - 58), RFA 56 (range 44 – 78) and overall 51 
(range, 32 – 78). Fourteen patients were male and 4 
female. At the time of primary diagnosis 11 patients 
had  stage  IV  disease  (5/11  liver,  5/11  lung,  2/11 
pleural, 1/11 brain, 1/11 bone ), 6 patients stage II and 
1 patient stage I. Patients and tumor specific charac-
teristics are depicted in Table 2. 
 
Table 2. Patient demographics and tumor specifics. 
#  Treatment  Age 
Dx 
Age at pro-
cedure 
Sex  Stage At Presen-
tation 
Genetic  Path  Synchronous vs 
Metachronous 
1  Surgery  35  47  Male  II  Familial  Papillary  Metachronous 
2  Surgery  56  61  Male  II  Sporadic  Clear cell  Metachronous 
3  Surgery  32  35  Male  II  Sporadic  Sarcomatoid  Metachronous 
4  Surgery  58  58  Male  IV  Sporadic  Granular  Synchronous 
5  Surgery  41  45  Male  II  Sporadic  Clear cell  Metachronous 
6  Surgery  49  50  Male  IV  Sporadic  Clear cell  Synchronous 
7  Surgery  47  47  Female  IV  Sporadic  Granular  Synchronous 
8  Surgery  56  56  Male  IV  Sporadic  Clear Cell  Synchronous 
9  Surgery  36  36  Female  IV  Sporadic  Clear Cell  Synchronous 
10  Surgery  45  47  Male  IV  Sporadic  Clear Cell  Metachronous 
11  RFA  50  55  Male  IV  Sporadic  Clear Cell  Metachronous 
12  RFA  44  49  Female  II  Sporadic  Clear Cell  Metachronous 
13  RFA  52  58  Male  IV  Sporadic  Clear Cell  Metachronous 
14  RFA  57  60  Male  IV  Sporadic  Clear Cell  Metachronous 
15  RFA  72  77  Male  II  Sporadic  Clear Cell  Metachronous 
16  RFA  54  55  Female  IV  Sporadic  Clear Cell  Metachronous 
17  RFA  78  84  Male  I  Sporadic  Clear Cell  Metachronous 
18  RFA 
 
62 
 
63  Male 
 
IV  Sporadic  Clear Cell  Metachronous 
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Table 3. Liver procedure demographics. 
 
 
Surgery (n = 10) 
Number of 
patients 
RFA (n = 8) 
Number of 
patients 
Liver Therapy     
Wedge Resection  4  0 
Trisegmentectomy  1  0 
Right Lobectomy  5  0 
RFA  0  8 
Number of Metastases     
1  7  7 
2  2  1 
3 – 4  1  0 
Size of Metastases (cm)     
unknown  1  1 
< 1  1  0 
2 – 3  1  5 
4 – 6  4  2 
6 - 10  3  0 
Laterality     
Right  9  6 
Left  1  1 
unknown  0  1 
NED  7  2 
NED (Liver)  10  8 
Residual Disease  (3)  (6) 
Lung  3  3 
Retroperitoneal  1  0 
Bone  0  1 
Mediastinal  0  1 
Intra-Abdominal   0  1 
Pleural  0  1 
Recurrence  (9)  (5) 
Renal Bed  1  0 
Pleural  1  1 
Lung  7  4 
Mediastinal  0  1 
Bone  1  1 
Retroperitoneal  1  0 
Brain  0  2 
LIVER  3  4 
Neo-Adjuvant Therapy     
IFN / IL2  4  0 
Adjuvant     
IFN / IL2  3  0 
TIL  1  0 
 
Primary Tumor Characteristics 
All 18 patients had histology confirmed renal cell 
carcinoma, sixteen clear cell tumors, one papillary and 
one  sarcomatoid  variant.  Two  patients  had  familial 
RCC, one Von Hippel-Lindau syndrome (VHL) and 
one hereditary leiomyomatosis and renal cell cancer 
(HLRCC).  Thirteen  patients  underwent  the  primary 
nephrectomy at the referring institutions. At time of 
diagnosis eleven patients had synchronous extra renal 
disease, and six patients had extra renal disease re-
sected at the time of initial operation. Resections of 
extra  renal  disease  included,  five  livers,  two  lungs, 
two adrenals and one retroperitoneal resection. Seven 
had no evidence  of disease following their primary 
surgery.  Four  patients  had  received  neo-adjuvant 
immunotherapy.  Three  received  adjuvant  immuno-
therapy  (interferon  (IFN)  and  high  dose  Interleu-
kin-2), and one received adjuvant adoptive cell trans-
fer with tumor infiltrating lymphocytes.  
Characteristics of liver metastases 
Liver metastases were metachronous in thirteen 
patients and synchronous in five patients. The median 
time  to  development  of  liver  metastases  from  the 
primary operation was 19.5 months (range, 0 to 142). 
Fourteen patients had single (surgery 7, RFA 7) and 
four  (surgery  3,  RFA  1)  had  multiple  liver  lesions, 
respectively.  Median  size  of  lesions  was  5cm  (0.5  – 
10cm) and 2.5cm (1 – 6cm) in the surgery and RFA 
groups respectively. Fifteen lesions were within  the 
right liver (surgery 9, RFA 6), two in the left (surgery 
1, RFA 1) and one unknown (RFA). Five patients un-
derwent right lobectomy, four wedge resections, one 
extended right hepatectomy and eight RFA. In those 
undergoing surgical resection all were rendered free 
of disease in the liver and 7/10 patients had no evi-
dence  of  disease  (NED)  systemically.  For  those  re-
ceiving RFA, two patients had an open RFA accom-
panying  resection  of  extra-hepatic  disease  and  the 
remaining six patients had percutaneous RFA leaving 
extra-hepatic disease following liver directed therapy. 
Details are depicted in Table 3. 
Clinical Outcomes and Prognostic Factors 
All patients resected were rendered free of dis-
ease  in  the  liver.  Morbidity  was  acceptable  and  in-
cluded blood transfusion (2/10) and wound infections 
(1/10).  Sixty  day  peri-operative  mortality  was  0%. 
Eleven (11/18) remained disease free in the liver (re-
section 7/10, RFA 4/8) at a median follow-up of 23.5 
months. Recurrent disease developed in fourteen pa-
tients (14/18) (9/10 resection, 5/8 RFA). Eleven pa-
tients recurred in the lung (resection 7/10, RFA 4/8). 
Liver recurrences were seen in seven patients (7/18) 
(surgery 3/10, RFA 4/8). Other recurrences included 
2/18 pleural, 1/18 renal bed, 2/18 pleural, 1/18 me-
diastinal,  2/18  bone,  1/18  retroperitoneal  and  2/18 
brain. Median time to any recurrence was 4 (1 - 18) 
and 6 (2 – 76) months for the surgery and RFA groups,  Journal of Cancer 2012, 3 
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respectively.  In  those  resected  to  NED  the  median 
disease free survival was 7.2 months and 1.2 months 
for the  surgery and  RFA  patients respectively. Pro-
gression  free  survival  from  liver  therapy  was  1.2 
months and 6 months (p=0.01), and disease free sur-
vival was 7 months and 1.2 months (p=0.56) for the 
surgery  and  RFA  groups,  respectively.  Median  DFI 
was  10  months  and  no  difference  was  observed  in 
those with a longer DFI (p = 0.95); liver specific pro-
gression free survival for the surgery and RFA groups 
were 4 and 6 months, respectively (p= 0.93). 
For the whole cohort, 1, 3 and 5-year actuarial 
survivals were 89%, 40%, 27%. Actuarial survivals for 
the  surgery  and  RFA  groups  were  not  significantly 
different, with 1, 3 and 5 year probabilities of survival 
of 79%, 45%, 34% and 100%, 33, and not reached, re-
spectively (p= 0.56, Figure 1). Median overall survival 
for the surgery cohort was 24 (3 to 254+) months, and 
for the RFA cohort 15.6 (7-56+) months. Synchronous 
disease  was  found  to  be negatively  associated  with 
survival in surgery patients. Those undergoing syn-
chronous resections lived a median of 1.1 years fol-
lowing liver resection compared to 5.7 years in those 
resected in the metachronous setting (p = 0.02; Figure 
2).  
 
Figure 1. Overall survival of the 18 patients who underwent liver resection (n = 10) or radiofrequency ablation (n = 8) for metastatic 
renal cell carcinoma.  The 5-year actuarial survival was 27% for all patients.  
 
Figure 2. Overall survival of the 10 patients who underwent synchronous versus metachronous liver resection for metastatic renal cell 
carcinoma.   Median survival for the synchronous group was 1.1 years versus 5.7 years in the metachronous group.    Journal of Cancer 2012, 3 
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We  did  not  see  statistical  significance  with  re-
spect  to  survival  according  to  the  number  of  liver 
metastases,  disease  free  interval  (DFI),  presence  of 
extra hepatic disease, resection of extra hepatic dis-
ease or rendering a patient completely NED. 
Discussion 
Approximately, 80% of patients with renal cell 
carcinoma will develop metastases; of these, 20-40% 
will develop liver disease. Historically, liver metasta-
ses have been an ominous prognostic feature. In fact, 
those with hepatic disease have been found to live a 
median of 7.4 months [4]. One may therefore state that 
tumor burden in the liver is often a rate limiting step 
for survival. The poor outcome of patients with liver 
metastases may partly be explained by the fact that, in 
most cases, liver metastases are multiple and occur in 
association with metastases to other sites which is in 
accordance with the hematogenous pattern of spread 
of RCC [5]. In fact, liver metastases of RCC are solitary 
in  only  2  to  4%  of  cases  [5].  The  question,  which 
therefore remains, is whether liver directed therapy 
with  or  without  extra  hepatic  disease  is  associated 
with increased survival?  
Response  to  systemic  therapy  remains  poor. 
Objective response rates are only seen in 15% of pa-
tients  with  high  dose  IL-2  and  chemotherapy  re-
sponses  remain  inferior.  In  the  modern  day  of 
hepatobiliary surgery mortality rates are low (0 – 2%) 
and morbidity rates are reasonable (33%) [3]. Thirty 
percent mortality associated with liver resection is no 
longer the case [6]. That being said, liver resection for 
metastatic  RCC  remains  controversial  and  there  is 
even less data supporting the use of RFA. Historically, 
the  majority  of  literature  documenting  resection  of 
RCC liver metastases came from case reports or small 
numbers of RCC patients included in liver resection 
manuscripts  for  noncolorectal,  nonneuroendocrine 
metastases [7] [8] [9]. More recently there have been 
four particular studies with 15 or more patients that 
produced thought provoking results. Median survival 
rates in these recent studies for patients undergoing 
resection  ranged  from  24  to  142  months  and  when 
compared  to  historical  controls  resection  remained 
superior (Table 3). However, one should remain cog-
nizant that all of these data sets are based on relatively 
small numbers of patients, biased and without rele-
vant control groups in the majority of studies.  
A more recent study was a comparative study in 
which  Staehler  et  al  reviewed  patients  undergoing 
liver resection for RCC and used a population of pa-
tients who refused liver resection as their control. To 
date, this is the only comparative study in the litera-
ture. They published a median survival of 142 months 
for patients undergoing liver resection for RCC with a 
median  5-year  survival  of  62.6%  [3].  These  results 
were superior to the control. Moreover, in contrast to 
previous studies these long term results are not infe-
rior to survival rates achieved with liver resection for 
colorectal metastases and are comparable to survival 
results of resection of pulmonary metastases for RCC, 
which are currently both generally accepted indica-
tions for an aggressive surgical approach [3] [10].  
The  other  finding  in  this  study  was  that  syn-
chronous liver metastases at initial diagnosis was as-
sociated  with  a  significantly  lower  survival  than 
metachronous  metastases.  Median  survival  was  155 
months with metachronous metastases compared to 
29 months in the synchronous group  [3]. Note that 
although the long term median survival could be in-
fluenced by the high proportion of patients (79%) re-
ceiving systemic therapy late in the course of disease, 
there  was  an  equal  proportion  of  patients  treated 
systemically in the synchronous group [3]. Although, 
one cannot conclude that the survival difference be-
tween the two groups may be an expression of liver 
resection  however  it  certainly  indicates  that  further 
studies should be performed in a scientific manner.  
Although proper selection criteria have yet to be 
established, the above studies have documented pos-
itive  prognostic  factors.  Studies  indicate  that  im-
proved survival was seen when the disease free in-
terval (DFI) to liver metastases was greater than 24 
months, metastases were less than 5cm and a R0 re-
section was performed [2] [10]. However, Thelen et al 
found that even in patients with a short DFI long-term 
survival can be achieved by hepatectomy [10].  
Unfortunately recurrence rates are high in those 
with  metastatic  RCC.  Most  studies  (including  our 
own) found that the disease recurs in the majority of 
patients  following  hepatectomy.  In  fact,  many  pa-
tients (50%) will recur within the first year [2]. Alt-
hough there is a paucity of data, repeat resection has 
been advocated by a number of groups. In particular, 
Aloia et al. found that patients who had recurrences in 
the  liver  following  resection  and  underwent  repeat 
hepatectomy  experienced  longer  survival  when 
compared  to  patients  who  were  not  re-resected  [2]. 
Further,  Alves  et  al  stated  that  due  to  the  constant 
tumor  recurrence  observed  after  liver  resection  an 
aggressive policy to treat hepatic metastases was as-
sociated with prolonged survival as demonstrated by 
the improved outcome of patients who were submit-
ted to repeat hepatectomy [5]. One may postulate that 
repeat resection may have the ability to prolong re-
mission when the tumor recurrence occurs in the liv-
er. A finding that a subset of patients with resectable 
recurrences  have  longer  survival  rates  when  com- Journal of Cancer 2012, 3 
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pared to patients with unresectable recurrences sup-
ports the argument that surgery with favorable biol-
ogy may be responsible for improved outcomes [2]. 
Therefore, we advocate close clinical follow up with 
computed tomography imaging in all resected or ab-
lated patients.   
In at least one multivariate model, debulking of 
greater than 90% of RCC metastases was associated 
with a significantly increased survival [11]. Therefore, 
one may presume that liver directed therapy for RCC 
may have increased efficacy if used in a multidisci-
plinary fashion. Kim et al concluded that surgical re-
section when performed in patients found to have a 
partial response to interleukin-2 for metastatic RCC 
increased survival [12]. We believe that in this era of 
new systemic options such as tyrosine kinase inhibi-
tors and other targeted based therapies, a more ag-
gressive  surgical  approach  may  be  appropriate  for 
patients with advanced RCC [11].  
When  analyzing  all  recent  studies  published 
(Table 1) 5 year survival rates are superior to historical 
controls with the most recent and largest two studies 
showing  5  year  survival  rates  of  43  –  62%  [3]  [13]. 
Moreover, these results compare favorably to those of 
hepatic resection for hepatic metastases [13]. Our se-
ries of patients adds to this limited data set and will 
hopefully lead to  hypothesis  generation in  order to 
formulate further trials. Limitations to our study are 
clear. It is a retrospective analysis with a small sample 
size and there is a selection bias for all patients who 
were  treated  at  the  National  Cancer  Institute,  NIH. 
We  believe  concrete  survival  conclusions  cannot  be 
drawn from this small sample size however; the re-
sults are intriguing and may help further other stud-
ies. Moreover, we argue that in the absence of alter-
native  treatments  of  demonstrated  efficacy  and  the 
poor natural prognosis of liver metastases from RCC 
an aggressive policy for achieving tumor eradication 
may offer a chance for long-term survival.  
Conclusions 
Although RCC metastatic to the liver portends a 
poor prognosis, our data and others suggest that, for 
some patients, liver resection may potentially result in 
improved survival. In our series, when compared to 
RFA, liver resection resulted in a trend for a longer 
median  survival.  We  propose  that  liver  resection  is 
safe and should be considered only in highly selected 
patients with metachronous disease and in a multi-
disciplinary manner.  
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